Seek Returns

ICLR vs. RVTY: ICON vs. Revvity Stock Comparison

How do ICON (ICLR) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

ICON (ICLR) and Revvity (RVTY) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for ICON (ICLR) and Revvity (RVTY)
Profile ItemICLRRVTY
NameICON plcRevvity Inc.
Country/RegionIrelandUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
GICS Sub-IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
Market Capitalization15.34 billion USD17.31 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateMay 15, 1998February 21, 1973
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ICLR
RVTY
GSPC
Loading price history…
ICON (ICLR) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for ICON (ICLR) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for ICON (ICLR) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for ICON (ICLR) and Revvity (RVTY)
MetricICLRRVTY
Total Return (1Y)30.55%76.75%
Total Return (3Y, Annualized)-6.05%24.22%
Total Return (5Y, Annualized)-5.40%-1.48%

Risk Profile

Drawdown History

ICLR
RVTY
GSPC
Loading price history…
ICON (ICLR) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for ICON (ICLR) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for ICON (ICLR) and Revvity (RVTY)
MetricICLRRVTY
Volatility (1Y, Annualized)68.62%40.22%
Beta (5Y)1.171.07
Max Drawdown (5Y)-76.87%-59.01%
Avg. Volume (3M)943.50K1.89M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ICLR and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for ICON (ICLR) and Revvity (RVTY)
MetricICLRRVTY
Sharpe Ratio (1Y)0.381.80
Sortino Ratio (1Y)0.522.90

Profitability

ROE (TTM)

Both ICON (ICLR) at 4.70% and Revvity (RVTY) at 3.45% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70%

Max
109.18%
Q3
6.23%
ICLR
4.70%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max
109.18%
Q3
6.23%
RVTY
3.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both ICON (ICLR) at 5.26% and Revvity (RVTY) at 8.61% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.26%

Max
18.05%
ICLR
5.26%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max
18.05%
RVTY
8.61%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Revvity (RVTY) at 17.06% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.73%

Max
83.12%
Q3
14.77%
ICLR
10.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max
83.12%
RVTY
17.06%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for ICON (ICLR) and Revvity (RVTY)
MetricICLRRVTY
ROE (TTM)4.70%3.45%
ROA (TTM)0.85%2.54%
Net Margin (TTM)5.26%8.61%
Operating Margin (TTM)10.73%17.06%
Gross Margin (TTM)23.44%55.91%

Growth

Revenue Growth

Both ICON (ICLR) at 0.76% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Revvity (RVTY) at -5.91% is around its peer norm for EPS growth, while ICON (ICLR) at -71.56% drops into the bottom quartile, signaling weaker earnings momentum.

Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for ICON (ICLR) and Revvity (RVTY)
MetricICLRRVTY
Revenue Growth (YoY)0.76%3.67%
Revenue Growth (3Y CAGR)2.15%-4.82%
EPS Growth (YoY)-71.56%-5.91%
EPS Growth (3Y CAGR)-23.82%-23.26%

Financial Strength

Current Ratio (MRQ)

Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while ICON (ICLR) at 1.32 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ICLR.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.32

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ICLR
1.32
Min
0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max
25.13
Q3
12.13
Median
5.52
RVTY
2.65
Q1
2.47
Min
0.10
Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both ICON (ICLR) at 0.38 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
ICLR
0.38
Median
0.15
Q1
0.02
Min
0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
RVTY
0.38
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for ICON (ICLR) and Revvity (RVTY)
MetricICLRRVTY
Current Ratio (MRQ)1.322.65
Debt / Equity (MRQ)0.380.38
Net Debt / EBITDA5.552.43

Dividends

Dividend Yield (TTM)

ICON (ICLR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY
0.19%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

ICON (ICLR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY
13.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for ICON (ICLR) and Revvity (RVTY)
MetricICLRRVTY
Dividend Yield (TTM)0.00%0.19%
Dividend Payout Ratio (TTM)0.00%13.40%

Valuation

P/E Ratio (TTM)

Both ICON (ICLR) at 81.90 and Revvity (RVTY) at 68.94 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.90

Max
85.34
ICLR
81.90
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max
85.34
RVTY
68.94
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Revvity (RVTY) at 5.88 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.86

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
ICLR
1.86
Min
0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max
58.18
Q3
25.77
Median
7.30
RVTY
5.88
Q1
3.01
Min
0.01
Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile against book while Revvity (RVTY) at 2.39 is valued near its industry’s middle — ICLR is cheaper on assets, though weigh it against ROE and asset quality.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.68

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
ICLR
1.68
Min
-5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max
13.53
Q3
6.54
Median
3.25
RVTY
2.39
Q1
1.69
Min
-5.59
Loading chart…
ICON (ICLR) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for ICON (ICLR) and Revvity (RVTY)
MetricICLRRVTY
P/E Ratio (TTM)81.9068.94
P/S Ratio (TTM)1.865.88
P/B Ratio (MRQ)1.682.39
Free Cash Flow Yield (TTM)3.51%3.62%